Treatment patterns and outcomes by mismatch repair/microsatellite instability status among patients with primary advanced or recurrent endometrial cancer in the United States.

ABSTRACT:

Aims

To describe real-world patient characteristics, treatment patterns, and clinical outcomes in primary advanced/recurrent endometrial cancer (pA/R EC) by mismatch repair/microsatellite instability (MMR/MSI) status who initiated first-line therapy.

Materials & methods

Data from the Flatiron Health electronic health record-derived database were analyzed from patients with a diagnosis of pA/R EC who started treatment between 1 January 2013, and 31 August 2022, from ≈ 280 US clinics. MMR/MSI status and treatment patterns were summarized; time to next treatment (TTNT) and overall survival (OS) were estimated using Kaplan-Meier methods.

Results

Of 2022 patients, 11.03%, 27.79%, and 61.18% had MMR-deficient/MSI-high (dMMR/MSI-H), MMR-proficient/microsatellite stable (MMRp

SUBMITTER: Chase DM 

PROVIDER: S-EPMC12323428 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature